Upgrade to SI Premium - Free Trial

Alnylam Pharmaceuticals (ALNY) PT Raised to $158 at Barclays on 3Q Report; 'Multiple Programs Progressing to Approval/Late-Stage Development'

November 8, 2017 11:54 AM
Barclays raised its price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $158.00 (from $127.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles